Ingenol Mebutate: Potential for Further Development of Cancer Immunotherapy

October 2012 | Volume 11 | Issue 10 | Original Article | 1156 | Copyright © 2012

Abstract

Ingenol mebutate is a diterpene ester derived from the plant Euphorbia peplus and is FDA approved for the topical treatment of actinic keratoses (AK). Shown to be efficacious with as little as a 3-day trial, this compound is being further tested for the topical treatment of other nonmelanoma skin cancers with promising preclinical data. In an effort to elucidate the molecular mechanism of this novel drug, Stahlhut et al.,(2012) suggest a role for calcium and apoptosis. Further studies are needed to evaluate the intracellular mechanisms of ingenol mebutate-mediated cytotoxicity. Additionally, studies such as this not only shed light on the mechanism of ingenol mebutate and its derivatives, but also pave the way for evaluating the involvement of the immune system in eliminating drug-treated cells and tissues. This has important implications for the development of novel topical immune modulatory products and the field of topical immunotherapy.

J Drugs Dermatol. 2012;11(10):1156-1157.

Purchase Original Article

Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.

Download the original manuscript as it was published in the JDD.

Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.

To get access to JDD's full-text articles and archives, upgrade here.

Save an unformatted copy of this article for on-screen viewing.

Print the full-text of article as it appears on the JDD site.

→ proceed | ↑ close

INTRODUCTION

Ingenol mebutate (Picato®) is a recently FDA approved topical agent for the treatment of actinic keratosis with as little as a 2 or 3 day treatment.1, 2 This drug has also been shown to be effective in treating superficial basal-cell cancer and is potentially effective in killing melanoma cells.3-5 How it works is still speculative, but this natural product, derived from the sap of the tree Euphorbia peplus, has been used extensively for its medicinal properties.2 In this issue of the Journal, Stahlhut et al. reveal for the first time evidence for the role of apoptosis and mitochondrial permeability as a possible mechanism of ingenol mebutate-mediated cytotoxicity. The authors demonstrate that ingenol mebutate elicits a strong and sustained increase in intracellular calcium that involves both ER-associated and mitochondrial-associated calcium stores. Interestingly, cancer cells take up ingenol mebutate and have a more robust calcium release promoting cell death upon treatment as compared to the same dose of ingenol mebutate in cultured donor keratinocytes. These findings are consistent with previous reports showing that ingenol mebutate specifically targets rapidly dividing cells in the basal cell layer (ie, dysplastic keratinocytes).

The findings in this study are the first to evaluate the intracellular mechanisms involved in how ingenol mebutate may promote dysplastic and neoplastic keratinocyte cell death and elimination while sparing normal keratinocytes. This study employed an in vitro method and utilized a model of reconstituted skin to demonstrate the localization of this novel compound. Future studies are needed to evaluate how this novel compound functions in vivo, especially considering how this compound implicates apoptosis and alternative death pathways in promoting cell death.

Ingenol mebutate treatment was shown to promote death of dysplastic and neoplastic skin cells and subsequently promoted keratinocyte proliferation in a mouse model of UVB-induced actinic keratosis and skin cancer.6 The authors of this earlier study suggest that early inflammation and neutrophil infiltration were the initiating events for regenerating keratinocytes at the basal layer. Additionally, Le et al. have further shown an immunostimulatory effect of ingenol mebutate resulting in an increase in anti-tumor CD8+ cells.7 Ingenol mebutate was also shown to differentially regulate apoptosis and TNF-α related apoptosis ligand (TRAIL) induced apoptosis in melanoma cancer cells.4 However, the apoptosis regulators are yet to be determined. Cozzi et al., showed that ingenol mebutate specifically targeted cells with mutant regulation of p53.6 Indeed, p53 expression and function are altered in cancer cells and thus ingenol mebutate may be acting on regulators of apoptosis. For instance, novel regulators such as the anti-apoptotic protein Fortilin are known to regulate p53, yet little else is known of this protein in relation to how apoptosis is modulated based on Fortilin-mediated regulation of p53.8 B-cell lymphoma-extra large (Bcl-xl) has further been shown to differentially regulate mitochondrial and ER-calcium stores.9 Other studies suggest a role for apoptotic regulators including Bcl proteins and the Protein Kinase C regulated Mitogen Activated Protein Kinase pathways (PKC-MAPK) in ingenol mebutate-mediated cell death.8-10 Additionally, the authors of the current study show a differential regulation of mitochondrial and ER stores of calcium. Apoptosis regulators in the Bcl-2 family, including Bcl-xL and Bax, are known to regulate calcium-mediated cell death yet the mechanisms are still to

↑ back to top


  • 1
  • 2

Related Articles